Study of Neurological Aging Among People Living With HIV
NCT ID: NCT05678660
Last Updated: 2025-06-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Total Enrollment
298 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-07-06
Study Completion Date
2028-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A prospective, exposure-control cohort study of older adults living with HIV comparing the neurological status of those who have had HIV infection for a longer period of time (long HIV group) to age, gender, and community-matched comparison group who have had HIV infection for a shorter period of time (short HIV group).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Imaging Reserve in NeuroHIV
NCT03596268
HIV
COMPLETED
Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific
NCT00168246
HIV Infections
HIV Related Neurological Diseases
UNKNOWN
Evaluation and Monitoring of Patients With HIV Infectionn
NCT00557570
HIV
COMPLETED
A Study of HIV-Disease Development in Aging
NCT00006144
HIV Infections
COMPLETED
PHASE2
Exercise Training to Improve Brain Health in Older HIV+ Individuals
NCT02663934
HIV
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is a substantial body of evidence that individuals with long-standing HIV infection experience accelerated neurological aging and prospective lifespan studies that incorporate neuropsychological and imaging outcomes are needed. Elevated risks of cerebrovascular disease are evident throughout the life course of persons living with HIV. Stroke risks are clearly increased in the first few months after antiretroviral initiation. Autopsy studies of adults with HIV 24-48 years of age showed all have vascular changes, specifically lymphocytic perivascular infiltration, thickening of arterial and arteriolar walls, widened perivascular space, hypertrophy of the vascular muscle layers and perivascular amyloid deposition. Even when excluding individuals with a history of stroke, cerebrovascular disease risk factors are associated with decreased cognitive capacity in persons with HIV. Basal ganglia enhancement on MRI indicative of decreased regional cerebral blood flow and blood brain barrier breakdown is associated with HIV dementia.
HIV-associated neurocognitive disorder is another manifestation of accelerated aging. Using diffusion tensor imaging and data from healthy controls to calculate an "brain age gaps" in individuals with HIV infection, the "brain age gap", is associated with plasma viral load and cognitive function. In an autopsy study comparing HIV+ persons age 36-60 years with age-matched controls, HIV showed increased amyloid beta immunostaining. The accumulation of these proteins may be one possible mechanisms of accelerated aging in HIV. Some have proposed that BBB breakdown secondary to vascular dysfunction may contribute to this deposition. Distal sensory polyneuropathy (DSPN), a common neurological comorbidity in HIV that also increases in frequency with age in HIV negative individuals. Despite extensive diagnostic evaluations, \~40% of people with a DSPN will have no clear underlying cause identified. DSPN is more common and complex in African population with additional underlying etiologies being medication toxicities and nutritional deficiencies.In the RAAZ study, investigators identified a high prevalence of DSPN among HIV infected individuals prior to ART initiation which is associated with low body mass index and food insecurity. More recent neuropathy studies have shown that folate deficiency may play a role in DSPN in Zambia with HIV+ individuals being especially susceptible. Epilepsy incidence shows a bimodal age distribution with the increased incidence of seizures and epilepsy in the elderly attributed to the increase of age-related and aging-related epileptogenic conditions. While the overall prevalence of epilepsy can be expected to increase with advanced age in HIV, identifying risk factors for this among persons for epilepsy among those with controlled systemic disease may offer important insights into the pathophysiology.
HIV-associated accelerated aging of the nervous system is thought to be related to ongoing low grade inflammation in the setting of treated HIV. Poor CNS penetration of some antiretroviral therapies (ARVs) has also been proposed as one problem contributing to neurological morbidity in systemically controlled HIV. ARV neurotoxicity is also important. Multiple studies have highlighted both the short and long term neurotoxicity of efavirenz. Darunavir and ritonavir may increase the risk of aging-related cerebral degeneration. Heneka 2020 proposed that COVID survivors may be at increased risk of neurological disorders due to direct negative effects of SARS-CoV-2, acceleration of pre-existing problems or de novo induction of neurodegenerative process. Poor complex motor performance in persons with HIV is associated with higher inflammatory burden. A recent report from Ghana found stroke admissions and mortality rates have increased since SARS-CoV-2's arrival.
In the SNAP Study, the investigators will utilize the existing consortia of neuro-HIV rural study sites to enroll 150 HIV+ adults \>45 years of age stable on ARVs for at least 7 years and an age, gender, and community-matched comparison group of HIV+ adults stable on ARVs for 1-2 years. These individuals will undergo annual assessments for 6 years to evaluate their general and neurological health and the aging process that evolves during the 6 years of assessments.
Understanding whether or not PLWH experience accelerated aging of the nervous system will provide critical insights for health services planning as antiretroviral therapies allow PLWH to live into middle and late years. Identifying risk factors for specific neurologic aging issues will guide clinical care and screening and may inform regarding the pathophysiological mechanisms involved including the possibility that some therapies contribute to the long-term neurotoxicity of the condition.
HIV-associated neurocognitive disorder is another manifestation of accelerated aging. Using diffusion tensor imaging and data from healthy controls to calculate an "brain age gaps" in individuals with HIV infection, the "brain age gap", is associated with plasma viral load and cognitive function. In an autopsy study comparing HIV+ persons age 36-60 years with age-matched controls, HIV showed increased amyloid beta immunostaining. The accumulation of these proteins may be one possible mechanisms of accelerated aging in HIV. Some have proposed that BBB breakdown secondary to vascular dysfunction may contribute to this deposition. Distal sensory polyneuropathy (DSPN), a common neurological comorbidity in HIV that also increases in frequency with age in HIV negative individuals. Despite extensive diagnostic evaluations, \~40% of people with a DSPN will have no clear underlying cause identified. DSPN is more common and complex in African population with additional underlying etiologies being medication toxicities and nutritional deficiencies.In the RAAZ study, investigators identified a high prevalence of DSPN among HIV infected individuals prior to ART initiation which is associated with low body mass index and food insecurity. More recent neuropathy studies have shown that folate deficiency may play a role in DSPN in Zambia with HIV+ individuals being especially susceptible. Epilepsy incidence shows a bimodal age distribution with the increased incidence of seizures and epilepsy in the elderly attributed to the increase of age-related and aging-related epileptogenic conditions. While the overall prevalence of epilepsy can be expected to increase with advanced age in HIV, identifying risk factors for this among persons for epilepsy among those with controlled systemic disease may offer important insights into the pathophysiology.
HIV-associated accelerated aging of the nervous system is thought to be related to ongoing low grade inflammation in the setting of treated HIV. Poor CNS penetration of some antiretroviral therapies (ARVs) has also been proposed as one problem contributing to neurological morbidity in systemically controlled HIV. ARV neurotoxicity is also important. Multiple studies have highlighted both the short and long term neurotoxicity of efavirenz. Darunavir and ritonavir may increase the risk of aging-related cerebral degeneration. Heneka 2020 proposed that COVID survivors may be at increased risk of neurological disorders due to direct negative effects of SARS-CoV-2, acceleration of pre-existing problems or de novo induction of neurodegenerative process. Poor complex motor performance in persons with HIV is associated with higher inflammatory burden. A recent report from Ghana found stroke admissions and mortality rates have increased since SARS-CoV-2's arrival.
In the SNAP Study, the investigators will utilize the existing consortia of neuro-HIV rural study sites to enroll 150 HIV+ adults \>45 years of age stable on ARVs for at least 7 years and an age, gender, and community-matched comparison group of HIV+ adults stable on ARVs for 1-2 years. These individuals will undergo annual assessments for 6 years to evaluate their general and neurological health and the aging process that evolves during the 6 years of assessments.
Understanding whether or not PLWH experience accelerated aging of the nervous system will provide critical insights for health services planning as antiretroviral therapies allow PLWH to live into middle and late years. Identifying risk factors for specific neurologic aging issues will guide clinical care and screening and may inform regarding the pathophysiological mechanisms involved including the possibility that some therapies contribute to the long-term neurotoxicity of the condition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Aging, Premature
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Long Group
Older adults individuals with longstanding HIV, stable and on antiretroviral therapy for at least 7 years
No interventions assigned to this group
Short Group
Older adults living with HIV, on stable antiretroviral treatment for at least 1 but not more than 2 years,
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For the short group, stable on ART for 1 year, but no more than 2 years.
* For long group, on ART for 7 or more years
* For long group, on ART for 7 or more years
Exclusion Criteria
* Acute medical illness.
* Decisional impairment precluding informed consent as noted by clinicians providing care to the patient or by the research staff team members.
* Communication impairments-unable to hear or unable to speak.
* Being unable to communicate in English or in the dominant language at the study site (Tonga).
* Decisional impairment precluding informed consent as noted by clinicians providing care to the patient or by the research staff team members.
* Communication impairments-unable to hear or unable to speak.
* Being unable to communicate in English or in the dominant language at the study site (Tonga).
Minimum Eligible Age
45 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Sponsor Role
collaborator
Centre for Infectious Disease Research in Zambia
OTHER
Sponsor Role
collaborator
University of Rochester
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gretchen Birbeck
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gretchen L. Birbeck, MD
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chilenje Level 1 Hospital
Lusaka, Lusaka Province, Zambia
Site Status
Chikankata Hospital
Mazabuka, Southern Province, Zambia
Site Status
Monze Mission Hospital
Monze, Southern Province, Zambia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Zambia
References
Explore related publications, articles, or registry entries linked to this study.
Mbewe EG, Kabundula PP, Mwanza-Kabaghe S, Buda A, Adams HR, Schneider C, Potchen MJ, Mweemba M, Mathews M, Menon JA, Wang B, Baseler T, Paciorkowski A, Birbeck GL, Bearden DR. Socioeconomic Status and Cognitive Function in Children With HIV: Evidence From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study. J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):56-63. doi: 10.1097/QAI.0000000000002825.
Reference Type
BACKGROUND
Bearden DR, Omech B, Rulaganyang I, Sesay SO, Kolson DL, Kasner SE, Mullen MT. Stroke and HIV in Botswana: A prospective study of risk factors and outcomes. J Neurol Sci. 2020 Jun 15;413:116806. doi: 10.1016/j.jns.2020.116806. Epub 2020 Mar 26.
Reference Type
BACKGROUND
Dean O, Buda A, Adams HR, Mwanza-Kabaghe S, Potchen MJ, Mbewe EG, Kabundula PP, Moghaddam SM, Birbeck GL, Bearden DR. Brain Magnetic Resonance Imaging Findings Associated With Cognitive Impairment in Children and Adolescents With Human Immunodeficiency Virus in Zambia. Pediatr Neurol. 2020 Jan;102:28-35. doi: 10.1016/j.pediatrneurol.2019.08.014. Epub 2019 Sep 9.
Reference Type
BACKGROUND
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020 Jun 4;12(1):69. doi: 10.1186/s13195-020-00640-3.
Reference Type
BACKGROUND
Kvalsund M, Kayamba V, Kelly P, Birbeck GL, Mwansa-Thurman C, Sommer IN, Lamers Y, Gardiner J, Herrmann DN. Is folate deficiency a common cause of distal symmetric polyneuropathy in Zambian clinics? J Neurol Sci. 2020 Feb 15;409:116583. doi: 10.1016/j.jns.2019.116583. Epub 2019 Nov 20.
Reference Type
BACKGROUND
Monreal E, Gullon P, Perez-Torre P, Escobar-Villalba A, Acebron F, Quereda Rodriguez-Navarro C, Sanchez-Ruano L, Fernandez-Felix BM, Muriel A, Perez-Elias MJ, Masjuan J, Corral I. Increased HIV infection in patients with stroke in Spain. A 16-year population-based study. Enferm Infecc Microbiol Clin (Engl Ed). 2020 May;38(5):219-225. doi: 10.1016/j.eimc.2019.10.006. Epub 2019 Dec 16. English, Spanish.
Reference Type
BACKGROUND
Sarfo FS, Mensah NO, Opoku FA, Adusei-Mensah N, Ampofo M, Ovbiagele B. COVID-19 and stroke: Experience in a Ghanaian healthcare system. J Neurol Sci. 2020 Sep 15;416:117044. doi: 10.1016/j.jns.2020.117044. Epub 2020 Jul 16.
Reference Type
BACKGROUND
Barrell K, Smith AG. Peripheral Neuropathy. Med Clin North Am. 2019 Mar;103(2):383-397. doi: 10.1016/j.mcna.2018.10.006. Epub 2018 Dec 17.
Reference Type
BACKGROUND
Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019 Jul 9;140(2):e98-e124. doi: 10.1161/CIR.0000000000000695. Epub 2019 Jun 3.
Reference Type
BACKGROUND
Hammond CK, Eley B, Ing N, Wilmshurst JM. Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa-A Retrospective Case Series. Front Neurol. 2019 Jul 9;10:742. doi: 10.3389/fneur.2019.00742. eCollection 2019.
Reference Type
BACKGROUND
Kuhn T, Jin Y, Huang C, Kim Y, Nir TM, Gullett JM, Jones JD, Sayegh P, Chung C, Dang BH, Singer EJ, Shattuck DW, Jahanshad N, Bookheimer SY, Hinkin CH, Zhu H, Thompson PM, Thames AD. The joint effect of aging and HIV infection on microstructure of white matter bundles. Hum Brain Mapp. 2019 Oct 15;40(15):4370-4380. doi: 10.1002/hbm.24708. Epub 2019 Jul 4.
Reference Type
BACKGROUND
Lin HL, Muo CH, Lin CY, Chen HJ, Chen PC. Incidence of stroke in patients with HIV infection: A population-based study in Taiwan. PLoS One. 2019 May 22;14(5):e0217147. doi: 10.1371/journal.pone.0217147. eCollection 2019.
Reference Type
BACKGROUND
Mapoure Njankouo Y, Mondomobe Atchom C, Halle MP, Mbatchou Ngahane BH, Luma NH. Prevalence of HIV infection among stroke patients in Douala. Med Sante Trop. 2019 May 1;29(2):184-189. doi: 10.1684/mst.2019.0895.
Reference Type
BACKGROUND
Montoya JL, Campbell LM, Paolillo EW, Ellis RJ, Letendre SL, Jeste DV, Moore DJ. Inflammation Relates to Poorer Complex Motor Performance Among Adults Living With HIV on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):15-23. doi: 10.1097/QAI.0000000000001881.
Reference Type
BACKGROUND
Pluta A, Wolak T, Sobanska M, Gawron N, Egbert AR, Szymanska B, Horban A, Firlag-Burkacka E, Bienkowski P, Sienkiewicz-Jarosz H, Scinska-Bienkowska A, Desowska A, Rusiniak M, Biswal BB, Rao S, Bornstein R, Skarzynski H, Lojek E. HIV and age underlie specific patterns of brain abnormalities and cognitive changes in high functioning patients. Neuropsychology. 2019 Mar;33(3):358-369. doi: 10.1037/neu0000504. Epub 2019 Jan 28.
Reference Type
BACKGROUND
Beghi E, Giussani G. Aging and the Epidemiology of Epilepsy. Neuroepidemiology. 2018;51(3-4):216-223. doi: 10.1159/000493484. Epub 2018 Sep 25.
Reference Type
BACKGROUND
Benjamin L, Khoo S. HIV infection and stroke. Handb Clin Neurol. 2018;152:187-200. doi: 10.1016/B978-0-444-63849-6.00015-3.
Reference Type
BACKGROUND
Cross HM, Chetty S, Asukile MT, Hussey HS, Lee Pan EB, Tucker LM. A proposed management algorithm for late-onset efavirenz neurotoxicity. S Afr Med J. 2018 Mar 28;108(4):271-274. doi: 10.7196/SAMJ.2017.v108i4.12914.
Reference Type
BACKGROUND
Gordon SB, Chinula L, Chilima B, Mwapasa V, Dadabhai S, Mlombe Y; Malawi Research Ethics Workshop 2018 Participants. A Malawi guideline for research study participant remuneration. Wellcome Open Res. 2018 Dec 19;3:141. doi: 10.12688/wellcomeopenres.14668.2. eCollection 2018.
Reference Type
BACKGROUND
Kvalsund M, Chidumayo T, Hamel J, Herrmann D, Heimburger D, Peltier A, Birbeck G. Factors associated with distal symmetric polyneuropathies in adult Zambians: A cross-sectional, observational study of the role of HIV, non-antiretroviral medication exposures, and nutrition. J Neurol Sci. 2018 May 15;388:61-69. doi: 10.1016/j.jns.2018.02.035. Epub 2018 Feb 22.
Reference Type
BACKGROUND
Seden K, Kiiza D, Laker E, Arinaitwe WJ, Waitt C, Lamorde M, Khoo S. High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. J Antimicrob Chemother. 2018 Nov 1;73(11):3158-3161. doi: 10.1093/jac/dky298.
Reference Type
BACKGROUND
Soontornniyomkij V, Umlauf A, Soontornniyomkij B, Gouaux B, Ellis RJ, Levine AJ, Moore DJ, Letendre SL. Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS. 2018 Sep 10;32(14):2005-2015. doi: 10.1097/QAD.0000000000001927.
Reference Type
BACKGROUND
Dickens AM, Yoo SW, Chin AC, Xu J, Johnson TP, Trout AL, Hauser KF, Haughey NJ. Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging. Sci Rep. 2017 Aug 10;7(1):7748. doi: 10.1038/s41598-017-07570-5.
Reference Type
BACKGROUND
Kuhn T, Schonfeld D, Sayegh P, Arentoft A, Jones JD, Hinkin CH, Bookheimer SY, Thames AD. The effects of HIV and aging on subcortical shape alterations: A 3D morphometric study. Hum Brain Mapp. 2017 Feb;38(2):1025-1037. doi: 10.1002/hbm.23436. Epub 2016 Oct 25.
Reference Type
BACKGROUND
Nookala AR, Mitra J, Chaudhari NS, Hegde ML, Kumar A. An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge? J Alzheimers Dis. 2017;60(s1):S169-S193. doi: 10.3233/JAD-170473.
Reference Type
BACKGROUND
Sandkovsky U, Podany AT, Fletcher CV, Owen A, Felton-Coleman A, Winchester LC, Robertson K, Swindells S. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. J Antimicrob Chemother. 2017 Jan;72(1):200-204. doi: 10.1093/jac/dkw403. Epub 2016 Sep 21.
Reference Type
BACKGROUND
Cysique LA, Brew BJ. The effects of HIV and aging on brain functions: proposing a research framework and update on last 3 years' findings. Curr Opin HIV AIDS. 2014 Jul;9(4):355-64. doi: 10.1097/COH.0000000000000078.
Reference Type
BACKGROUND
Andras IE, Toborek M. Amyloid beta accumulation in HIV-1-infected brain: The role of the blood brain barrier. IUBMB Life. 2013 Jan;65(1):43-9. doi: 10.1002/iub.1106. Epub 2012 Dec 7.
Reference Type
BACKGROUND
Cettomai D, Kwasa JK, Birbeck GL, Price RW, Cohen CR, Bukusi EA, Kendi C, Meyer AC. Screening for HIV-associated peripheral neuropathy in resource-limited settings. Muscle Nerve. 2013 Oct;48(4):516-24. doi: 10.1002/mus.23795. Epub 2013 Aug 27.
Reference Type
BACKGROUND
Chang L, Holt JL, Yakupov R, Jiang CS, Ernst T. Lower cognitive reserve in the aging human immunodeficiency virus-infected brain. Neurobiol Aging. 2013 Apr;34(4):1240-53. doi: 10.1016/j.neurobiolaging.2012.10.012. Epub 2012 Nov 15.
Reference Type
BACKGROUND
Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012 Oct;11(10):878-90. doi: 10.1016/S1474-4422(12)70205-3.
Reference Type
BACKGROUND
Birbeck GL, Kvalsund MP, Byers PA, Bradbury R, Mang'ombe C, Organek N, Kaile T, Sinyama AM, Sinyangwe SS, Malama K, Malama C. Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. Am J Trop Med Hyg. 2011 Oct;85(4):782-9. doi: 10.4269/ajtmh.2011.11-0187.
Reference Type
BACKGROUND
Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B; HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011 Mar 13;25(5):625-33. doi: 10.1097/QAD.0b013e3283427da7.
Reference Type
BACKGROUND
Clark US, Cohen RA. Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs. 2010 Aug;11(8):884-900.
Reference Type
BACKGROUND
Foley J, Ettenhofer M, Wright MJ, Siddiqi I, Choi M, Thames AD, Mason K, Castellon S, Hinkin CH. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol. 2010 Feb;24(2):265-85. doi: 10.1080/13854040903482830.
Reference Type
BACKGROUND
Kandiah PA, Atadzhanov M, Kvalsund MP, Birbeck GL. Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1380-1. doi: 10.1136/jnnp.2009.183210. Epub 2010 Jun 11.
Reference Type
BACKGROUND
Achim CL, Adame A, Dumaop W, Everall IP, Masliah E; Neurobehavioral Research Center. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009 Jun;4(2):190-9. doi: 10.1007/s11481-009-9152-8. Epub 2009 Mar 17.
Reference Type
BACKGROUND
Birbeck GL, Chomba E, Kvalsund M, Bradbury R, Mang'ombe C, Malama K, Kaile T, Byers PA, Organek N; RAAZ Study Team. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009 Apr;80(4):669-74.
Reference Type
BACKGROUND
Chang L, Wong V, Nakama H, Watters M, Ramones D, Miller EN, Cloak C, Ernst T. Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol. 2008 Dec;3(4):265-74. doi: 10.1007/s11481-008-9120-8. Epub 2008 Aug 15.
Reference Type
BACKGROUND
Chomba E, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL. The socioeconomic status of children with epilepsy in Zambia: implications for long-term health and well-being. Epilepsy Behav. 2008 Nov;13(4):620-3. doi: 10.1016/j.yebeh.2008.06.008. Epub 2008 Aug 12.
Reference Type
BACKGROUND
Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005 Sep 2;19(13):1367-74.
Reference Type
BACKGROUND
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
Reference Type
BACKGROUND
Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, Asthana D, Fujimura RK, Lee D, van Zuilen MH, Khamis I, Shapshak P, Eisdorfer C. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol. 2001 Dec;54 Suppl 1:S35-43. doi: 10.1016/s0895-4356(01)00445-0.
Reference Type
BACKGROUND
44. WHO. The Alcohol Use Disorders Identification Test 2nd edition. Online: WHO; 2001: http://www.who.int/substance_abuse/publications/en/.
Reference Type
BACKGROUND
Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A, Avison MJ. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology. 2000 Feb 22;54(4):921-6. doi: 10.1212/wnl.54.4.921.
Reference Type
BACKGROUND
Dufouil C, Clayton D, Brayne C, Chi LY, Dening TR, Paykel ES, O'Connor DW, Ahmed A, McGee MA, Huppert FA. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination. Neurology. 2000 Dec 12;55(11):1609-13. doi: 10.1212/wnl.55.11.1609.
Reference Type
BACKGROUND
Fazeka F, Ropele S, Bammer R, Kapeller P, Stollberger R, Schmidt R. Novel imaging technologies in the assessment of cerebral ageing and vascular dementia. J Neural Transm Suppl. 2000;59:45-52. doi: 10.1007/978-3-7091-6781-6_7.
Reference Type
BACKGROUND
Izycka-Swieszewska E, Zoltowska A, Rzepko R, Gross M, Borowska-Lehman J. Vasculopathy and amyloid beta reactivity in brains of patients with acquired immune deficiency (AIDS). Folia Neuropathol. 2000;38(4):175-82.
Reference Type
BACKGROUND
Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry. 1983 Jan;140(1):41-6. doi: 10.1176/ajp.140.1.41.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSRB_STUDY00007234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study
NCT02592174
COMPLETED
NA
Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
NCT00675766
COMPLETED
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
NCT05586581
RECRUITING
PHASE1/PHASE2
Acute HIV Infection Observational Study
NCT00296660
COMPLETED
Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS
NCT02470351
COMPLETED
Geriatric HIV Cohort in Sub Sahara Africa
NCT04313699
UNKNOWN
Effects of Anti-HIV Therapy on Nervous System Function
NCT00432003
COMPLETED
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
NCT00001103
COMPLETED
Thinking and Memory Problems in People With HIV
NCT01875588
RECRUITING
Observational PIC Destination Cohort
NCT05985642
RECRUITING
The Targeted Neurocognitive Training (TNT) Study
NCT05773430
SUSPENDED
NA
A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175
NCT00096824
COMPLETED
Speed of Processing Training in Adults With HIV
NCT02758093
COMPLETED
NA
Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders
NCT01665846
COMPLETED
PHASE1
HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy
NCT04266002
COMPLETED
NA
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
NCT01202305
RECRUITING
Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
NCT02555930
COMPLETED
Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)
NCT01186042
COMPLETED
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
NCT03239899
COMPLETED
PHASE1
Stanford Universities: The Stanford HIV Aging Cohort
NCT01401348
COMPLETED
Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV
NCT00782808
COMPLETED
Revealing Increased Axonal Loss in Treated HIV Patients
NCT02003989
COMPLETED
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
NCT00796146
RECRUITING
Aging With HIV and Neurocognitive Decline, a Follow-up Study
NCT05385588
COMPLETED
NA